189 related articles for article (PubMed ID: 23672654)
21. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients.
Carswell CJ; Win Z; Muckle K; Kennedy A; Waldman A; Dawe G; Barwick TD; Khan S; Malhotra PA; Perry RJ
J Neurol Neurosurg Psychiatry; 2018 Mar; 89(3):294-299. PubMed ID: 29018162
[TBL] [Abstract][Full Text] [Related]
23. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
24. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
25. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
26. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Trembath L; Newell M; Devous MD
J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of amyloid PET using
Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
[TBL] [Abstract][Full Text] [Related]
28. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.
Sevigny J; Suhy J; Chiao P; Chen T; Klein G; Purcell D; Oh J; Verma A; Sampat M; Barakos J
Alzheimer Dis Assoc Disord; 2016; 30(1):1-7. PubMed ID: 26885819
[TBL] [Abstract][Full Text] [Related]
29. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
[TBL] [Abstract][Full Text] [Related]
30. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
Clark CM; Pontecorvo MJ; Beach TG; Bedell BJ; Coleman RE; Doraiswamy PM; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Arora A; Carpenter AP; Flitter ML; Joshi AD; Krautkramer MJ; Lu M; Mintun MA; Skovronsky DM;
Lancet Neurol; 2012 Aug; 11(8):669-78. PubMed ID: 22749065
[TBL] [Abstract][Full Text] [Related]
31. Amyloid imaging with [(18)F]florbetapir in geriatric depression: early-onset versus late-onset.
Tateno A; Sakayori T; Higuchi M; Suhara T; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 Jul; 30(7):720-8. PubMed ID: 25335941
[TBL] [Abstract][Full Text] [Related]
32. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
Grundman M; Johnson KA; Lu M; Siderowf A; Dell'Agnello G; Arora AK; Skovronsky DM; Mintun MA; Pontecorvo MJ;
Dement Geriatr Cogn Disord; 2016; 41(1-2):80-92. PubMed ID: 26745445
[TBL] [Abstract][Full Text] [Related]
33. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.
Akhtar RS; Xie SX; Chen YJ; Rick J; Gross RG; Nasrallah IM; Van Deerlin VM; Trojanowski JQ; Chen-Plotkin AS; Hurtig HI; Siderowf AD; Dubroff JG; Weintraub D
PLoS One; 2017; 12(5):e0177924. PubMed ID: 28542444
[TBL] [Abstract][Full Text] [Related]
34. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
[TBL] [Abstract][Full Text] [Related]
35. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Lim YY; Maruff P; Getter C; Snyder PJ
Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
[TBL] [Abstract][Full Text] [Related]
36. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
Hornberger J; Bae J; Watson I; Johnston J; Happich M
Curr Med Res Opin; 2017 Apr; 33(4):675-685. PubMed ID: 28035842
[TBL] [Abstract][Full Text] [Related]
37. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
Carome M; Wolfe S
JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
[No Abstract] [Full Text] [Related]
38. Amyloid PET/MRI in the differential diagnosis of dementia.
Vercher-Conejero JL; Rubbert C; Kohan AA; Partovi S; O'Donnell JK
Clin Nucl Med; 2014 Jun; 39(6):e336-9. PubMed ID: 23856830
[TBL] [Abstract][Full Text] [Related]
39. A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid Load.
Loewenstein DA; Curiel RE; Greig MT; Bauer RM; Rosado M; Bowers D; Wicklund M; Crocco E; Pontecorvo M; Joshi AD; Rodriguez R; Barker WW; Hidalgo J; Duara R
Am J Geriatr Psychiatry; 2016 Oct; 24(10):804-13. PubMed ID: 27160985
[TBL] [Abstract][Full Text] [Related]
40. Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.
James OG; Linares AR; Hellegers C; Doraiswamy PM; Wong TZ
Clin Nucl Med; 2021 Jul; 46(7):605-608. PubMed ID: 33443955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
